TY  - JOUR
A1  - Hausmann, Stefan
A1  - Brandt, Evelyn
A1  - Köchel, Carolin
A1  - Einsele, Hermann
A1  - Bargou, Ralf C.
A1  - Seggewiss-Bernhardt, Ruth
A1  - Stühmer, Thorsten
T1  - Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines
JF  - PLoS ONE
N2  - Multiple myeloma (MM) is a generally fatal plasma cell cancer that often shows activation of the phosphoinositide 3-kinase/Akt (PI3K/Akt) pathway. Targeted pharmacologic therapies, however, have not yet progressed beyond the clinical trial stage, and given the complexity of the PI3K/Akt signalling system (e.g. multiple protein isoforms, diverse feedback regulation mechanisms, strong variability between patients) it is mandatory to characterise its ramifications in order to better guide informed decisions about the best therapeutic approaches. Here we explore whether serum and glucocorticoid-regulated kinase 3 (SGK3), a potential downstream effector of PI3K, plays a role in oncogenic signalling in MM cells-either in concert with or independent of Akt. SGK3 was expressed in all MM cell lines and in all primary MM samples tested. Four MM cell lines representing a broad range of intrinsic Akt activation (very strong: MM. 1s, moderate: L 363 and JJN-3, absent: AMO-1) were chosen to test the effects of transient SGK3 knockdown alone and in combination with pharmacological inhibition of Akt, PI3K-p110\(\alpha\), or in the context of serum starvation. Although the electroporation protocol led to strong SGK3 depletion for at least 5 days its absence had no substantial effect on the activation status of potential downstream substrates, or on the survival, viability or proliferation of MM cells in all experimental contexts tested. We conclude that it is unlikely that SGK3 plays a significant role for oncogenic signalling in multiple myeloma.
KW  - Akt
KW  - phosphorylation
KW  - downstream
KW  - mechanism
KW  - pathway
KW  - isoforms
KW  - activation
KW  - cancer
KW  - inhibition
KW  - phosphatidylinositol 3-kinase/Akt
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148708
VL  - 10
IS  - 4
ER  - 
TY  - JOUR
A1  - Rickman, Kimberly A.
A1  - Lach, Francis P.
A1  - Abhyankar, Avinash
A1  - Donovan, Frank X.
A1  - Sanborn, Erica M.
A1  - Kennedy, Jennifer A.
A1  - Sougnez, Carrie
A1  - Gabriel, Stacey B.
A1  - Elemento, Olivier
A1  - Chandrasekharappa, Settara C.
A1  - Schindler, Detlev
A1  - Auerbach, Arleen D.
A1  - Smogorzewska, Agata
T1  - Deficiency of UBE2T, the E2 Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T Subtype of Fanconi Anemia
JF  - Cell Reports
N2  - Fanconi anemia (FA) is a rare bone marrow failure and cancer predisposition syndrome resulting from pathogenic mutations in genes encoding proteins participating in the repair of DNA interstrand crosslinks (ICLs). Mutations in 17 genes (FANCA-FANCS) have been identified in FA patients, defining 17 complementation groups. Here, we describe an individual presenting with typical FA features who is deficient for the ubiquitin-conjugating enzyme (E2), UBE2T. UBE2T is known to interact with FANCL, the E3 ubiquitin-ligase component of the multiprotein FA core complex, and is necessary for the monoubiquitination of FANCD2 and FANCI. Proband fibroblasts do not display FANCD2 and FANCI monoubiquitination, do not form FANCD2 foci following treatment with mitomycin C, and are hypersensitive to crosslinking agents. These cellular defects are complemented by expression of wild-type UBE2T, demonstrating that deficiency of the protein UBE2T can lead to Fanconi anemia. UBE2T gene gains an alias of FANCT.
KW  - cross-link repair
KW  - DNA repair
KW  - gene
KW  - mutations
KW  - aldehydes
KW  - somatic mosaicism
KW  - pathway
KW  - monoubiquitination
KW  - diagnosis
KW  - proteins
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-151525
VL  - 12
SP  - 35
EP  - 41
ER  -